SEC Comment Letter 0000000000-24-006984 to Aditxt, Inc. (ADTX)
Aditxt, Inc.
Date: June 18, 2024 · CIK: 0001726711 · Accession: 0000000000-24-006984
AI Filing Summary & Sentiment
File numbers found in text: 001-39336
Show Raw Text
United States securities and exchange commission logo
June 18, 2024
Amro Albanna
Chief Executive Officer
Aditxt, Inc.
737 N. Fifth Street, Suite 200
Richmond, VA 23219
Re:Aditxt, Inc.
Revised Preliminary Proxy Statement on Schedule 14A
Filed June 18, 2024
File No. 001-39336
Dear Amro Albanna:
We have reviewed your filing and have the following comment.
Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe a
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments.
Revised Preliminary Proxy Statement on Schedule 14A
General
1.We note your response to prior comment 3 and reissue. Your Form 8-K filed December
26, 2023 indicates that you entered the Exchange Agreement in connection with the
Merger Agreement making it appear that the Exchange Agreement is not separate and
apart from the Merger Agreement. Please revise your preliminary proxy statement to
provide the disclosures required by Items 11, 13 and 14 of Schedule 14A with respect to
those matters, as applicable, pursuant to Note A of Schedule 14A. Alternatively, please
provide us with a more detailed analysis supporting why such disclosure is not required.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Please contact Daniel Crawford at 202-551-7767 or Jason Drory at 202-551-8342 with
any other questions.
FirstName LastNameAmro Albanna
Comapany NameAditxt, Inc.
June 18, 2024 Page 2
FirstName LastName
Amro Albanna
Aditxt, Inc.
June 18, 2024
Page 2
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Sean Reid, Esq.